ARQT RSI Chart
Last 7 days
0.6%
Last 30 days
-21.6%
Last 90 days
15.9%
Trailing 12 Months
-20.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 17.7M | 31.6M | 45.6M | 59.6M |
2022 | 0 | 0 | 0 | 3.7M |
2021 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | matsuda masaru | sold | -43,828 | 8.7378 | -5,016 | see remark |
May 02, 2024 | burnett patrick | sold | -83,489 | 8.7378 | -9,555 | see remarks |
May 02, 2024 | watanabe todd franklin | sold | -120,433 | 8.7378 | -13,783 | see remarks |
May 02, 2024 | moore matthew richard | sold | -40,901 | 8.7378 | -4,681 | svp and chief business officer |
May 01, 2024 | moore matthew richard | acquired | - | - | 4,166 | svp and chief business officer |
Apr 10, 2024 | topper david joseph | acquired | - | - | 110,000 | chief financial officer |
Mar 04, 2024 | heron patrick j | bought | 199,994 | 9.5 | 21,052 | - |
Mar 04, 2024 | burnett patrick | sold | -53,181 | 11.1212 | -4,782 | see remarks |
Mar 04, 2024 | moore matthew richard | sold | -38,568 | 11.1212 | -3,468 | svp and chief business officer |
Mar 04, 2024 | matsuda masaru | sold | -41,815 | 11.1212 | -3,760 | see remark |
Which funds bought or sold ARQT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | CITIGROUP INC | added | 5,535 | 7,058,860 | 7,099,920 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 28.43 | 205,269 | 275,082 | -% |
May 10, 2024 | VANGUARD GROUP INC | added | 5.51 | 35,383,500 | 51,199,200 | -% |
May 10, 2024 | Rubric Capital Management LP | added | 13.03 | 52,962,300 | 74,424,100 | 2.20% |
May 10, 2024 | DIMENSIONAL FUND ADVISORS LP | sold off | -100 | -383,230 | - | -% |
May 10, 2024 | Symmetry Investments LP | sold off | -100 | -178,000 | - | -% |
May 10, 2024 | Pacer Advisors, Inc. | new | - | 38,401 | 38,401 | -% |
May 10, 2024 | Vontobel Holding Ltd. | unchanged | - | 140,280 | 208,110 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 1,299 | 9,681,210 | 9,912,040 | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | added | 2.53 | 66,002 | 96,761 | -% |
Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Arcutis Biotherapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Arcutis Biotherapeutics Inc News
Income Statement (Quarterly) | ||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2021Q4 |
Revenue | -64.5% | 14.00 | 38.00 | 5.00 | 3.00 | 2.00 | 1.00 | - |
Cost Of Revenue | -100.0% | - | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | - |
Operating Expenses | -100.0% | - | 75.00 | 72.00 | 79.00 | 71.00 | 105 | 71.00 |
S&GA Expenses | 2.3% | 49.00 | 48.00 | 46.00 | 43.00 | 37.00 | 35.00 | 19.00 |
R&D Expenses | -9.4% | 24.00 | 26.00 | 25.00 | 35.00 | 54.00 | 30.00 | 53.00 |
Interest Expenses | 2.7% | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 5.00 | - |
Income Taxes | -99.6% | 0.00 | 3.00 | - | - | - | - | - |
Net Income | -48.1% | -66.28 | -44.76 | -70.99 | -80.10 | -72.02 | -107 | -71.33 |
Net Income Margin | 25.1% | -4.40* | -5.87* | -10.45* | -18.52* | -84.50* | - | - |
Free Cashflow | -27.7% | -56.25 | -44.05 | -66.76 | -80.43 | -71.19 | -67.70 | -51.97 |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Assets | 16.5% | 341 | 293 | 321 | 379 | 449 | 509 | 300 | 364 | 408 | 387 | 433 | 471 | 298 | 198 | 232 | 254 | 107 |
Current Assets | 17.4% | 330 | 282 | 309 | 368 | 437 | 497 | 295 | 359 | 403 | 382 | 428 | 466 | 293 | 194 | 228 | 254 | 106 |
Cash Equivalents | -16.9% | 89.00 | 107 | 105 | 81.00 | 55.00 | 83.00 | 63.00 | 71.00 | 98.00 | 53.00 | 91.00 | 290 | 67.00 | 46.00 | 172 | 191 | 63.00 |
Inventory | -5.6% | 13.00 | 14.00 | 10.00 | 9.00 | 8.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -11.3% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 2.6% | 253 | 246 | 240 | 240 | 240 | 238 | 105 | 110 | 110 | 24.00 | 18.00 | 20.00 | 28.00 | 25.00 | 23.00 | 13.00 | 6.00 |
Current Liabilities | 11.4% | 47.00 | 42.00 | 37.00 | 37.00 | 38.00 | 37.00 | 27.00 | 33.00 | 33.00 | 19.00 | 13.00 | 15.00 | 23.00 | 21.00 | 19.00 | 12.00 | 5.00 |
Long Term Debt | 0.5% | 202 | 201 | 200 | 199 | 198 | 197 | 73.00 | 73.00 | 72.00 | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 0.5% | 202 | 201 | 200 | 199 | 198 | 197 | 73.00 | 73.00 | 72.00 | - | - | - | - | - | - | - | - |
Shareholder's Equity | 89.8% | 89.00 | 47.00 | 81.00 | 140 | 210 | 271 | 195 | 254 | 298 | 363 | 414 | 451 | 271 | 173 | 209 | 242 | - |
Retained Earnings | -7.2% | -981 | -915 | -870 | -799 | -719 | -647 | -540 | -472 | -408 | -336 | -280 | -238 | -202 | -167 | -129 | -94.28 | -66.30 |
Additional Paid-In Capital | 11.2% | 1,071 | 963 | 952 | 940 | 930 | 920 | 737 | 727 | 706 | 700 | 695 | 689 | 473 | 341 | 339 | 336 | 1.00 |
Shares Outstanding | 56.5% | 97.00 | 62.00 | 62.00 | 61.00 | 61.00 | 53.00 | 51.00 | 51.00 | 49.00 | 50.00 | 50.00 | 47.00 | - | - | - | - | - |
Float | - | - | - | 487 | - | - | - | 878 | - | - | - | 1,082 | - | - | - | 620 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -27.9% | -56,244 | -43,984 | -66,485 | -80,344 | -71,065 | -67,695 | -61,980 | -56,975 | -51,709 | -40,884 | -35,831 | -46,203 | -32,571 | -33,691 | -25,761 | -21,010 | -16,797 | -10,722 | -8,243 | -7,074 | - |
Share Based Compensation | -12.4% | 8,757 | 9,999 | 10,578 | 9,479 | 9,264 | 8,789 | 8,096 | 6,533 | 5,686 | 5,363 | 4,340 | 8,503 | 2,643 | 2,261 | 2,049 | 990 | 455 | 154 | 139 | 76.00 | - |
Cashflow From Investing | -236.5% | -62,186 | 45,549 | 89,118 | 107,751 | 42,201 | -197,262 | 52,565 | 15,297 | 23,499 | 3,471 | -164,919 | 61,996 | -75,892 | -91,711 | 6,105 | -20,326 | -35,999 | 21,096 | -2,152 | -9,270 | - |
Cashflow From Financing | 11352.0% | 99,289 | 867 | 1,067 | 100 | 962 | 284,989 | 1,131 | 14,716 | 72,881 | 63.00 | 1,188 | 207,815 | 129,380 | -437 | 309 | 168,893 | 92,955 | -20.00 | 168 | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total revenues | $ 59,606,000 | $ 3,686,000 | $ 0 |
Operating expenses: | |||
Cost of sales | 4,987,000 | 754,000 | 0 |
Research and development | 110,575,000 | 182,435,000 | 145,558,000 |
Selling, general and administrative | 185,145,000 | 122,124,000 | 60,971,000 |
Total operating expenses | 300,707,000 | 305,313,000 | 206,529,000 |
Loss from operations | (241,101,000) | (301,627,000) | (206,529,000) |
Other income (expense): | |||
Other income, net | 11,786,000 | 5,821,000 | 173,000 |
Interest expense | (29,712,000) | (15,652,000) | 0 |
Loss before income taxes | (259,027,000) | (311,458,000) | (206,356,000) |
Provision for income taxes | 3,113,000 | 0 | 0 |
Net loss | (262,140,000) | (311,458,000) | (206,356,000) |
Other comprehensive income (loss): | |||
Unrealized loss on marketable securities | 1,186,000 | (831,000) | (253,000) |
Foreign currency translation adjustment | (96,000) | 0 | 0 |
Total other comprehensive income (loss) | 1,090,000 | (831,000) | (253,000) |
Comprehensive loss | $ (261,050,000) | $ (312,289,000) | $ (206,609,000) |
Per share information: | |||
Net loss per share, basic (in USD per share) | $ (3.78) | $ (5.66) | $ (4.18) |
Net loss per share, diluted (in USD per share) | $ (3.78) | $ (5.66) | $ (4.18) |
Weighted-average shares used in computing net loss per share, basic (in shares) | 69,305,487 | 55,032,265 | 49,405,575 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 69,305,487 | 55,032,265 | 49,405,575 |
Product revenue, net | |||
Revenues: | |||
Total revenues | $ 29,186,000 | $ 3,686,000 | $ 0 |
Other revenue | |||
Revenues: | |||
Total revenues | $ 30,420,000 | $ 0 | $ 0 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 88,398 | $ 53,641 |
Restricted cash | 925 | 1,234 |
Marketable securities | 183,463 | 355,948 |
Trade receivables, net | 25,807 | 8,458 |
Inventory | 13,134 | 7,514 |
Prepaid expenses and other current assets | 18,704 | 10,611 |
Total current assets | 330,431 | 437,406 |
Property and equipment, net | 1,539 | 1,881 |
Intangible assets, net | 6,438 | 7,188 |
Operating lease right-of-use asset | 2,361 | 2,721 |
Other assets | 596 | 78 |
Total assets | 341,365 | 449,274 |
Current liabilities: | ||
Accounts payable | 11,992 | 8,827 |
Accrued liabilities | 33,941 | 28,323 |
Operating lease liability | 735 | 657 |
Total current liabilities | 46,668 | 37,807 |
Operating lease liability, noncurrent | 3,382 | 4,117 |
Long-term debt, net | 201,799 | 197,769 |
Other long-term liabilities | 849 | 0 |
Total liabilities | 252,698 | 239,693 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized; 96,787,343 and 61,052,250 shares issued at December 31, 2023 and 2022, respectively; 96,787,343 and 61,037,403 shares outstanding at December 31, 2023 and 2022, respectively | 9 | 6 |
Additional paid-in capital | 1,070,558 | 930,425 |
Accumulated other comprehensive income (loss) | 4 | (1,086) |
Accumulated deficit | (981,904) | (719,764) |
Total stockholders’ equity | 88,667 | 209,581 |
Total liabilities and stockholders’ equity | $ 341,365 | $ 449,274 |